Conclusion: EOS884448 is a highly potent antagonist against TIGIT mAb that:

- Binds with high affinity to human and cynomolgus TIGIT T cells.
- Competes for binding with TIGIT ligands.
- Increases IFNγ secretion in human primary T cells from healthy donors and cancer patients in vitro.
- All at sub-nM concentrations.
- Preferentially depletes human Tregs in vivo.

When replaced by a mouse surrogate with identical properties:

- Inverts the immunosuppressive Treg/CD8+ T cell ratio and restores CD8+ T cell function.
- Promotes antitumor immunity as monotherapy or in combination with anti-PD1 in CT26 colon carcinoma mouse model.